JP2023550626A5 - - Google Patents
Info
- Publication number
- JP2023550626A5 JP2023550626A5 JP2023530765A JP2023530765A JP2023550626A5 JP 2023550626 A5 JP2023550626 A5 JP 2023550626A5 JP 2023530765 A JP2023530765 A JP 2023530765A JP 2023530765 A JP2023530765 A JP 2023530765A JP 2023550626 A5 JP2023550626 A5 JP 2023550626A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- polypeptide
- masked
- sequence
- polypeptide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117307P | 2020-11-23 | 2020-11-23 | |
| US63/117,307 | 2020-11-23 | ||
| US202163177935P | 2021-04-21 | 2021-04-21 | |
| US63/177,935 | 2021-04-21 | ||
| US202163195673P | 2021-06-01 | 2021-06-01 | |
| US63/195,673 | 2021-06-01 | ||
| US202163250990P | 2021-09-30 | 2021-09-30 | |
| US63/250,990 | 2021-09-30 | ||
| PCT/US2021/060357 WO2022109399A1 (en) | 2020-11-23 | 2021-11-22 | Tgf-beta polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550626A JP2023550626A (ja) | 2023-12-04 |
| JP2023550626A5 true JP2023550626A5 (enExample) | 2025-01-07 |
Family
ID=81709765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530765A Pending JP2023550626A (ja) | 2020-11-23 | 2021-11-22 | ＴＧＦ－βポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230416321A1 (enExample) |
| EP (1) | EP4247431A4 (enExample) |
| JP (1) | JP2023550626A (enExample) |
| CA (1) | CA3174130A1 (enExample) |
| WO (1) | WO2022109399A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250151519A (ko) * | 2023-02-20 | 2025-10-21 | 아케소 바이오파마 컴퍼니 리미티드 | TGF-βRII 세포 외 영역 단편을 포함하는 융합 단백질, 및 이의 약제학적 조성물, 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110165623A1 (en) * | 2004-01-06 | 2011-07-07 | The Government Of The U.S. As Represented By The Secretary, Dept. Of Health & Human Services | Compositions and Methods for the High Efficiency Expression of the Transforming Growth Factor-Beta Supergene Family |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| JP5841845B2 (ja) * | 2009-02-24 | 2016-01-13 | ソーク・インステチュート・フォー・バイオロジカル・スタディーズＳａｌｋ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｌｏｇｉｃａｌ Ｓｔｕｄｉｅｓ | ＴＧＦ−βスーパーファミリーのデザイナーリガンド |
| ES2948647T3 (es) * | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
-
2021
- 2021-11-22 US US18/038,402 patent/US20230416321A1/en active Pending
- 2021-11-22 EP EP21895762.9A patent/EP4247431A4/en active Pending
- 2021-11-22 WO PCT/US2021/060357 patent/WO2022109399A1/en not_active Ceased
- 2021-11-22 JP JP2023530765A patent/JP2023550626A/ja active Pending
- 2021-11-22 CA CA3174130A patent/CA3174130A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| JP7597836B2 (ja) | 骨標的抗体 | |
| JP7627517B2 (ja) | 抗ｃｄ７３抗体、抗体薬物複合体、及びその使用 | |
| JP7421338B2 (ja) | 免疫調節融合タンパク質 | |
| JP2021512899A5 (enExample) | ||
| US5767260A (en) | Antigen-binding fusion proteins | |
| EP1071468B1 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor | |
| JP2020143115A (ja) | 片頭痛の治療または予防法 | |
| JP2019137675A5 (enExample) | ||
| CN112040985A (zh) | 用于递送治疗性蛋白质的方法和组合物 | |
| JP2016105714A (ja) | 代替軽鎖の発現 | |
| CA2328081A1 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor | |
| CA3152776A1 (en) | Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment | |
| CN106573966A (zh) | 用于治疗代谢异常的组合物和方法 | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| CA3073560A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| JP2023537292A (ja) | ＳＩＲＰα－Ｆｃ融合タンパク質 | |
| JP2021518132A (ja) | Ｇｉｐｒ抗体及びｇｌｐ−１とのその融合タンパク質、並びにその医薬組成物及び用途 | |
| JP2023550626A5 (enExample) | ||
| JP2022513321A5 (enExample) | ||
| CA3073331A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| JP7239987B2 (ja) | 薬物送達のための抗体融合タンパク質 | |
| US20220257729A1 (en) | Combination of integrin-targeting knottin-fc fusion and anti-cd47 antibody for the treatment of cancer | |
| WO2020221136A1 (zh) | 一种蛋白质异二聚体及其用途 |